BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Hidradenitis suppurativa clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for hidradenitis suppurativa: 60 (30 sponsors; 12 newly posted in the last 180 days, 2 stopped in the last 180 days; 6 new-entrant sponsors). Momentum score 22.5, rank 19 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 7, Phase 2 22, Phase 3 13, Phase 4 1, N/A 17.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Incyte Corporation INCY | 6 | P3 4, P1 1, P2 1 | 0 | 2 |
| Novartis Pharmaceuticals NVS | 14 | NA 9, P3 3, P4 1, P1 1 | 3 | 4 |
| AbbVie ABBV | 5 | NA 1, P2 2, P3 2 | 0 | 2 |
| Institut Pasteur | 2 | NA 1, P3 1 | 0 | 1 |
| UCB Biopharma SRL | 2 | P1 1, P3 1 | 0 | 1 |
| Bluefin Biomedicine, Inc. | 1 | P3 1 | 0 | 0 |
| MoonLake Immunotherapeutics AG MLTX | 1 | P3 1 | 0 | 0 |
| Sanofi SNY | 4 | P1 1, P2 3 | 2 | 1 |
| Almirall, S.A. | 2 | P2 2 | 0 | 1 |
| Sonoma Biotherapeutics, Inc. SNOA | 2 | P1 1, NA 1 | 0 | 0 |
| Target PharmaSolutions, Inc. TGT | 2 | NA 2 | 1 | 0 |
| Aroa Biosurgery Limited | 1 | NA 1 | 0 | 0 |
| Citryll BV | 1 | P2 1 | 0 | 1 |
| Corvus Pharmaceuticals, Inc. CRVS new entrant | 1 | P1 1 | 1 | 0 |
| Integra LifeSciences Corporation IART new entrant | 1 | NA 1 | 1 | 0 |
| Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | 1 | P2 1 | 0 | 0 |
| Merck Sharp & Dohme LLC MRK | 1 | P2 1 | 0 | 0 |
| Navigator Medicines, Inc. NVGS | 1 | P2 1 | 0 | 0 |
| Oruka Therapeutics, Inc. ORKA new entrant | 1 | P2 1 | 1 | 0 |
| Pfizer PFE | 1 | P2 1 | 0 | 1 |
| Power Life Sciences Inc. | 1 | NA 1 | 0 | 0 |
| Qilu Pharmaceutical Co., Ltd. | 1 | P2 1 | 0 | 0 |
| Regeneron Pharmaceuticals REGN new entrant | 1 | P2 1 | 1 | 0 |
| Shanghai Huaota Biopharmaceutical Co., Ltd. | 1 | P2 1 | 0 | 0 |
| Shanghai Qilu Pharmaceutical Research and Development Center LTD | 1 | P1 1 | 0 | 0 |
New-entrant sponsors: Corvus Pharmaceuticals, Inc., Integra LifeSciences Corporation, Oruka Therapeutics, Inc., Regeneron Pharmaceuticals.
Recently stopped trials
- NCT06685835 Insmed Incorporated - terminated: Lack of Efficacy A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
- NCT06241573 Boehringer Ingelheim - terminated: A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurat
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | AbbVie ABBV | NCT06468228 A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | active not recruiting | 1400 |
| 2026-12-08 est. | P2 | Pfizer PFE | NCT07228390 A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradeniti | Hidradenitis Suppurativa | active not recruiting | 128 |
| 2026-12-21 est. | P3 | UCB Biopharma SRL | NCT06921850 A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | active not recruiting | 43 |
| 2026-12-26 est. | P3 | Incyte Corporation INCY | NCT06212999 A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa (HS) | active not recruiting | 617 |
| 2027-02 est. | P2 | AbbVie ABBV | NCT06524635 A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receivin | Hidradenitis Suppurativa; Atopic Dermatitis | recruiting | 60 |
| 2027-02 est. | P2 | Almirall, S.A. | NCT07547813 A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa | Hidradenitis Suppurativa | recruiting | 50 |
| 2027-02-05 est. | P2 | Takeda TAK | NCT07244263 A Study of Zasocitinib in Adults With Hidradenitis Suppurativa | Hidradenitis Suppurativa | active not recruiting | 91 |
| 2027-02-09 est. | P2 | Sanofi SNY | NCT07170917 Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | recruiting | 208 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-29 | P3 | Incyte Corporation INCY | NCT06959225 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) | Hidradenitis Suppurativa | active not recruiting | 580 |
| 2026-10-01 | P3 | Incyte Corporation INCY | NCT06958211 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) | Hidradenitis Suppurativa | active not recruiting | 573 |
| 2026-09-28 | P3 | MoonLake Immunotherapeutics AG MLTX | NCT06768671 An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurat | Hidradenitis Suppurativa | completed | 35 |
| 2026-09-18 | P2 | Zura Bio Inc ZURA | NCT06993610 Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense | Hidradenitis Suppurativa (HS) | active not recruiting | 247 |
| 2026-07-22 | P3 | UCB Biopharma SRL | NCT04901195 A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | completed | 658 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "hidradenitis suppurativa"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.